GPX2 and prostate carcinoma: Exploiting microRNA molecules, such as miR-17, to target antioxidant enzymes is involved in prostate cancer cell proliferation, and it has been reported that increasing miR-17 inhibits the growth of PC-3 cells by eliminating critical primary mitochondrial antioxidant enzymes, such as manganese superoxide dismutase (MnSOD), GPX2, and TXNRD2 [94].